The estimated Net Worth of Adam S Grossman is at least $45.2 Millón dollars as of 26 August 2024. Mr. Grossman owns over 626,245 units of Adma Biologics Inc stock worth over $41,413,977 and over the last 11 years he sold ADMA stock worth over $2,109,500. In addition, he makes $1,702,020 as President, Chief Executive Officer, Co-Founder y Director at Adma Biologics Inc.
Adam has made over 40 trades of the Adma Biologics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 626,245 units of ADMA stock worth $2,905,777 on 26 August 2024.
The largest trade he's ever made was exercising 2,100,459 units of Adma Biologics Inc stock on 15 August 2023 worth over $6,532,427. On average, Adam trades about 65,007 units every 57 days since 2013. As of 26 August 2024 he still owns at least 2,449,082 units of Adma Biologics Inc stock.
You can see the complete history of Mr. Grossman stock trades at the bottom of the page.
Adam S. Grossman serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Mr. Grossman has been a director of the Company since 2007, has served as the Company’s President and Chief Executive Officer since October 2011 and as the Company’s President and Chief Operating Officer between 2007 and October 2011. Mr. Grossman has over 20 years of experience in the blood and plasma industry. Prior to founding the Company, Mr. Grossman was the Executive Vice President of National Hospital Specialties at GenesisBPS, a position he held between 1994 and 2011. He has experience in launching new products, building and managing national and international sales forces, managing clinical trials and completing numerous business development transactions. Previously, he worked at MedImmune, Inc., where he worked on marketing teams for RSV and CMV immunoglobulins, and at the American Red Cross, where he launched new products with the Biomedical Services division. Mr. Grossman received a B.S. in Business Administration, with a specialization in International Business and Marketing, from American University. Mr. Grossman is the son of Dr. Jerrold B. Grossman, our Vice Chairman and co-founder. Mr. Grossman was chosen to serve on the Board because, as the Company’s Chief Executive Officer, he is able to provide the Board with critical insight into the day-to-day operations of the Company.
As the President, Chief Executive Officer, Co-Founder y Director of Adma Biologics Inc, the total compensation of Adam Grossman at Adma Biologics Inc is $1,702,020. There are no executives at Adma Biologics Inc getting paid more.
Adam Grossman is 43, he's been the President, Chief Executive Officer, Co-Founder y Director of Adma Biologics Inc since 2011. There are 12 older and no younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.
Adam's mailing address filed with the SEC is 465 New Jersey 17 S, Ramsey, NJ 07446, United States.
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... y Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Inc executives and other stock owners filed with the SEC include: